Dr Reddy's has a significant presence in North America where it has partnered with leading pharmaceutical companies including Merck & Co, to bring the first authorized generics of simvastatin and finasteride to the USA in 2006-7. In the US, we rank among the top 12 generic companies, with 34 product families being marketed and a large pipeline pending approval.
In Europe, Dr Reddy's is an emerging player that has taken a leading position in the key genericised molecules with a significant presence in the UK and Germany and partners in Italy, Spain, France, Nordic countries and the Netherlands. In the UK, we have more than 30 products
in the market. Our acquisition of Betapharm, Germany’s 5th largest generics company, further consolidated our presence in the European Union (EU), with 145 products in the market.
Dr Reddy's also have wholly-owned subsidiaries in Russia, Brazil and New Zealand and joint-ventures in China, South- Africa and Australia.
All manufacturing plants are approved by the required regulatory bodies.
